Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?
This article was originally published in The Pink Sheet Daily
At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.
You may also be interested in...
The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.
With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.
Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.